Company news
Heron Therapeutics, Inc. news in 2021
Heron Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®
December 8, 2021
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
November 17, 2021
Heron Therapeutics to Present at Upcoming Investor Conferences
November 10, 2021
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates
November 2, 2021
Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021
October 27, 2021
Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting
October 3, 2021
Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
August 8, 2021
Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery
July 27, 2021
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
July 20, 2021
Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™
July 5, 2021
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours
June 30, 2021
Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference
May 24, 2021
Heron Therapeutics Announces $150 Million Convertible Debt Financing
May 24, 2021
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
May 12, 2021
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates
May 9, 2021
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
February 23, 2021
Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences
February 16, 2021
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
January 20, 2021
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
January 10, 2021
Calls in 2021
Decks in 2021
- Corporate Update (May 2021)
Corporate update · 34 slides · May 13, 2021
- Corporate Update (January 2021)
Corporate update · 65 slides · Jan 11, 2021